Results 121 to 130 of about 3,125,328 (279)

Clinical validation of a DNA methylation biomarker associated with overall survival of relapsed ovarian cancer patients

International Journal of Cancer, EarlyView.
What's New? Most patients with ovarian cancer (OC) relapse after first‐line chemotherapy, and prognosis with second‐line treatment depends largely on the platinum‐free interval. However, reliable biomarkers to predict response to second‐line therapy remain lacking.
Muhammad Habiburrahman, Nahal Masrour, Naina Patel, Anna M. Piskorz, Robert Brown, James D. Brenton, Iain A. McNeish, James M. Flanagan   +7 more
wiley   +1 more source

Supplementary Methods and Figure Legends from Plk1 Phosphorylation of Orc2 and Hbo1 Contributes to Gemcitabine Resistance in Pancreatic Cancer

, 2023
Bing Song, X. Shawn Liu, Steven J. Rice, Shihuan Kuang, Bennett D. Elzey, Stephen F. Konieczny, Timothy L. Ratliff, Tony R. Hazbun, Elena G. Chiorean, Xiaoqi Liu   +9 more
openalex   +1 more source

Screening anticancer peptides performance in organotypic prostate tumor‐stroma 3D models

International Journal of Cancer, EarlyView.
What's New? Peptide‐based drugs have emerged as promising anticancer therapies for their potential to disrupt protein–protein interactions. In this study, the authors developed a physiomimetic human 3D prostate cancer spheroid model to assess the efficacy of the CAVPENET peptide in inhibiting tumor growth. Upon incubation with CAVPENET, prostate cancer
Bárbara Matos, Maria V. Monteiro, Matilde R. Lagarto, John Howl, Carmen Jerónimo, Vítor M. Gaspar, João F. Mano, Margarida Fardilha   +7 more
wiley   +1 more source

Supplementary figure S1 from Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation

, 2023
Huai‐Qiang Ju, Takeshi Gocho, Mitzi Aguilar, Min Wu, Zhuonan Zhuang, Jie Fu, Katsuhiko Yanaga, Peng Huang, Paul J. Chiao   +8 more
openalex   +1 more source

Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum‐resistant ovarian cancer: Phase I expansion results

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective In the dose‐escalation part of Study 101, which included multiple tumor types, objective responses were observed in 10 of 22 patients across multiple dose levels of farletuzumab ecteribulin (FZEC). We explored the safety/antitumor activity of FZEC in patients with platinum‐resistant ovarian cancer (PROC) from the Study 101 expansion ...
Kan Yonemori, Mayu Yunokawa, Koji Matsumoto, Kazuhiro Takehara, Kosei Hasegawa, Yasuyuki Hirashima, Hidenori Kato, Hiroki Ikezawa, Yohei Otake, Wataru Yusa, Takuma Miura, Shin Nishio   +11 more
wiley   +1 more source

Beyond a Conduit: The Evolution of Functional Biliary Stents From Active Intervention to Enabling Platforms

iNew Medicine, EarlyView.
This review traces the evolution of functional biliary stents, outlining the paradigm shift from “active intervention” strategies that target stent failure to next‐generation “enabling platforms.” These platforms leverage biodegradable materials, 3D/4D printing, and smart sensors to achieve personalized, regenerative, and theranostic solutions ...
Muhan Li, Xu Liu, Xin Ye, Zhixia Dong, Xinjian Wan   +4 more
wiley   +1 more source

Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt

Journal of Cancer, 2011
A phase III clinical trial showed gemcitabine chemotherapy combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib significantly improved overall survival in patients with advanced pancreatic cancer.
Chandra Bartholomeusz, Fumiyuki Yamasaki, Hitomi Saso, Kaoru Kurisu, Gabriel N. Hortobagyi, Naoto T. Ueno
doaj  

Extracellular vesicle‐based vaccines and immunotherapeutics for treatment of cancer

Interdisciplinary Medicine, EarlyView.
This review highlights the innovative value of extracellular vesicles (EVs) as cancer vaccines and immunotherapy carriers. EVs have natural advantages such as low immunogenicity, high biocompatibility, stability, and precise targeting, enabling efficient delivery of tumor antigens (e.g., HER2, AFP) and immune stimulants (e.g., TLR ligands, cytokines ...
Lejia Tan, Haonan Xing, Fang Fang, Yuanyu Huang, Mei Lu   +4 more
wiley   +1 more source

Artificial intelligence strategies for predicting kinase inhibitor resistance: A comprehensive review of methods, challenges, and future perspectives

Journal of Intelligent Medicine, EarlyView.
Abstract Kinase inhibitors are essential in targeted cancer therapy, yet resistance often emerges through secondary mutations, activation of compensatory signaling pathways, or drug‐efflux mechanisms. Artificial intelligence (AI) provides a workflow‐based strategy rather than a list of unrelated tools for predicting and addressing kinase‐inhibitor ...
Faris Hassan, Mohanad Ali Deifallah, Alaa Zaghloul, Rania Elgohary   +3 more
wiley   +1 more source

Advances and Prospects of Stereotactic Radiosurgery and Stereotactic Ablative Body Radiotherapy: Evolving Paradigms in Precision Oncology

Med Research, EarlyView.
The graphical abstract outlines the progressive development and impact of stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT). Technological Evolution illustrates the transition from brachytherapy with single‐dose, LDR/HDR schedules to fractionated radiotherapy, three‐dimensional conformal radiotherapy (3DCRT) and Gamma Knife ...
Jing Zhang, Wenhao Xu, Weiqing Lu, Yingxuan Lin, Luoxi He, Zonglin Lv, Yiliyaer Nuerrula, Zouting, Zhen Zhang, Hailiang Zhang, Xuejun Ma   +10 more
wiley   +1 more source